These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 31644935)

  • 1. Rational particle design to overcome pulmonary barriers for obstructive lung diseases therapy.
    He Y; Liang Y; Han R; Lu WL; Mak JCW; Zheng Y
    J Control Release; 2019 Nov; 314():48-61. PubMed ID: 31644935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhalable drugs for systemic therapy.
    Corkery K
    Respir Care; 2000 Jul; 45(7):831-5. PubMed ID: 10926380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Substance deposition assessment in obstructed pulmonary system through numerical characterization of airflow and inhaled particles attributes.
    Lalas A; Nousias S; Kikidis D; Lalos A; Arvanitis G; Sougles C; Moustakas K; Votis K; Verbanck S; Usmani O; Tzovaras D
    BMC Med Inform Decis Mak; 2017 Dec; 17(Suppl 3):173. PubMed ID: 29297393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Aerosol therapy in obstructive respiratory tract diseases: deposition, administration methods, inhalation technics, inhalation aids].
    Niggemann B
    Ergeb Inn Med Kinderheilkd; 1989; 59():169-212. PubMed ID: 2686974
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluation of highly branched cyclic dextrin in inhalable particles of combined antibiotics for the pulmonary delivery of anti-tuberculosis drugs.
    Kadota K; Senda A; Tagishi H; Ayorinde JO; Tozuka Y
    Int J Pharm; 2017 Jan; 517(1-2):8-18. PubMed ID: 27913241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in the management of obstructive airways disease. Auxiliary MDI aerosol delivery systems.
    Sackner MA; Kim CS
    Chest; 1985 Aug; 88(2 Suppl):161S-170S. PubMed ID: 4017697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formulation of a novel fixed dose combination of salmeterol xinafoate and mometasone furoate for inhaled drug delivery.
    Liu S; Watts AB; Du J; Bui A; Hengsawas S; Peters JI; Williams RO
    Eur J Pharm Biopharm; 2015 Oct; 96():132-42. PubMed ID: 26220015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nano-salbutamol dry powder inhalation: a new approach for treating broncho-constrictive conditions.
    Bhavna ; Ahmad FJ; Mittal G; Jain GK; Malhotra G; Khar RK; Bhatnagar A
    Eur J Pharm Biopharm; 2009 Feb; 71(2):282-91. PubMed ID: 18984050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug transport across pulmonary epithelial cell monolayers: effects of particle size, apical liquid volume, and deposition technique.
    Bur M; Huwer H; Muys L; Lehr CM
    J Aerosol Med Pulm Drug Deliv; 2010 Jun; 23(3):119-27. PubMed ID: 20073555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advantages of pressurized canister metered dose inhalers.
    Newhouse M
    J Aerosol Med; 1991; 4(3):139-50. PubMed ID: 10147675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patented therapeutic drug delivery strategies for targeting pulmonary diseases.
    Thakur AK; Chellappan DK; Dua K; Mehta M; Satija S; Singh I
    Expert Opin Ther Pat; 2020 May; 30(5):375-387. PubMed ID: 32178542
    [No Abstract]   [Full Text] [Related]  

  • 12. Changing delivery methods for obstructive lung diseases.
    Dolovich M
    Curr Opin Pulm Med; 1997 May; 3(3):177-89. PubMed ID: 9232363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulmonary drug delivery: from generating aerosols to overcoming biological barriers-therapeutic possibilities and technological challenges.
    Ruge CA; Kirch J; Lehr CM
    Lancet Respir Med; 2013 Jul; 1(5):402-13. PubMed ID: 24429205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Beta2 agonists and anticholinergics. Inhalation therapy in acute deterioriation of asthma and chronic obstructive pulmonary disease].
    Ringbaek TJ; Phanareth K; Lange P
    Ugeskr Laeger; 1996 Oct; 158(42):5957-62. PubMed ID: 8928288
    [No Abstract]   [Full Text] [Related]  

  • 15. In Vitro Dosing Performance of the ELLIPTA® Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLung™).
    Hamilton M; Leggett R; Pang C; Charles S; Gillett B; Prime D
    J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):498-506. PubMed ID: 26372465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Formulation strategy and use of excipients in pulmonary drug delivery.
    Pilcer G; Amighi K
    Int J Pharm; 2010 Jun; 392(1-2):1-19. PubMed ID: 20223286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary deposition of lactose carriers used in inhalation powders.
    Karhu M; Kuikka J; Kauppinen T; Bergström K; Vidgren M
    Int J Pharm; 2000 Feb; 196(1):95-103. PubMed ID: 10675711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New treatments for chronic obstructive pulmonary disease and viable formulation/device options for inhalation therapy.
    Onoue S; Misaka S; Kawabata Y; Yamada S
    Expert Opin Drug Deliv; 2009 Aug; 6(8):793-811. PubMed ID: 19558334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhaled therapy in COPD: what are the benefits?
    Postma DS
    Respir Med; 1991 Nov; 85(6):447-9. PubMed ID: 1775669
    [No Abstract]   [Full Text] [Related]  

  • 20. Bronchodilator therapy for chronic obstructive pulmonary disease.
    Lu CC
    Respirology; 1997 Dec; 2(4):317-22. PubMed ID: 9525304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.